Together, this highlights N6-substituted adenosines as progenitor PINK1 activators thatcould potentially be developed, in the future, as treatments for agedand sporadic PD patients who have elevated phosphorylated ubiquitinlevels in the brain. The gene discussed is PINK1; the disease is Parkinson disease.